SMSbiotech is pleased to announce that Dr. Joseph Loewenbein, M.D. has joined the company as a Scientific Advisor, further strengthening its scientific and clinical leadership in regenerative medicine.

‍

Dr. Loewenbein is a board-certified anesthesiologist with more than 20 years of clinical experience and a focused expertise in regenerative and longevity medicine. A graduate of the Keck School of Medicine of the University of Southern California, he has built a career centered on advancing clinically grounded approaches to human health and physiological optimization.

‍

Over the course of his medical career, Dr. Loewenbein transitioned from anesthesiology into regenerative and longevity-focused medicine, applying his deep understanding of human physiology to the development of strategies designed to support tissue repair, immune system balance, and cellular health.

‍

He is also the co-founder of Proactive Longevity, where he developed a structured clinical framework focused on cellular optimization. His approach integrates key pillars including detoxification, immune system modulation, and regenerative support, helping expand patient access to next-generation therapeutic strategies grounded in clinical science.

‍

As Scientific Advisor to SMSbiotech, Dr. Loewenbein will contribute clinical insight and expertise in regenerative protocols to support the advancement of the company’s Small Mobile Stem (SMS) cell platform. His experience will help guide the translation of emerging cellular therapies into practical clinical applications for patients facing degenerative and chronic conditions.

‍

The addition of Dr. Loewenbein further strengthens SMSbiotech’s growing network of scientific and clinical advisors dedicated to advancing innovative regenerative medicine solutions.

‍